Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITDAEPS (Basic)EPS (Weighted Average and Diluted)Income towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Summit Therapeutics (SMMT) Revenue (2016 - 2022)

Summit Therapeutics filings provide 7 years of Revenue readings, the most recent being $220000.0 for Q3 2022.

  • Quarterly Revenue fell 83.19% to $220000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $220000.0 through Jun 2023, down 89.24% year-over-year, with the annual reading at $705000.0 for FY2022, 61.03% down from the prior year.
  • Revenue hit $220000.0 in Q3 2022 for Summit Therapeutics, down from $235000.0 in the prior quarter.
  • Across five years, Revenue topped out at $50.6 million in Q3 2018 and bottomed at $57000.0 in Q2 2021.
  • Average Revenue over 5 years is $3.3 million, with a median of $242500.0 recorded in 2022.
  • The largest annual shift saw Revenue plummeted 99.68% in 2019 before it skyrocketed 623.2% in 2021.
  • Summit Therapeutics' Revenue stood at $863000.0 in 2018, then crashed by 82.22% to $153473.5 in 2019, then grew by 20.54% to $185000.0 in 2020, then skyrocketed by 35.68% to $251000.0 in 2021, then decreased by 12.35% to $220000.0 in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Revenue are $220000.0 (Q3 2022), $235000.0 (Q2 2022), and $250000.0 (Q1 2022).